FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Swedish Orphan Biovitrum AB (publ) Stock AnalysisComprehensive stock analysis for Swedish Orphan Biovitrum AB (publ) (BIOVF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBIOVF
BIOVF
Swedish Orphan Biovitrum AB (publ)
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BIOVF
Home🔹Stocks🔹Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ)

BIOVF•OTC

Swedish Orphan Biovitrum AB (publ)

BIOVF•OTC
Market cap
$12.79B
Sentiment

Your view on BIOVF

Mkt Cap
$12.79B
Sentiment
Your view
BIOVF
Swedish Orphan Biovitrum AB (publ)
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
BIOVF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Swedish Orphan Biovitrum AB (publ)

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Guido Oelkers
Headquarters
Tomtebodavägen 23A, Solna, SE
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Guido Oelkers
Headquarters
Tomtebodavägen 23A, Solna, SE
Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News